Hiruma, Shigenori
Shigiyama, Fumika
Hisatake, Shinji
Mizumura, Sunao
Shiraga, Nobuyuki
Hori, Masaaki
Ikeda, Takanori
Hirose, Takahisa
Kumashiro, Naoki http://orcid.org/0000-0002-5432-3599
Funding for this research was provided by:
Boehringer Ingelheim
Eli Lilly Japan
Article History
Received: 9 December 2020
Accepted: 25 January 2021
First Online: 2 February 2021
Ethics approval and consent to participate
: All investigators involved in this study followed the “World Medical Association Declaration of Helsinki” (2013 revision), and “Ethical Guidelines for Medical and Health Research Involving Human Subjects” (December 22, 2014, Ministry of Education, Culture, Sports, Science and Technology/Ministry of Health, Labor and Welfare), and other laws and regulations. Written informed consent was obtained from all participants.
: Not applicable.
: NK received research funds from Nippon Boehringer Ingelheim Co., Ltd., and lecture fees from Takeda Pharmaceutical Company Ltd.; Ono Pharmaceutical Co., Ltd.; Mitsubishi Tanabe Pharma Corporation; and Nippon Boehringer Ingelheim Co., Ltd. TH received research funds from AstraZeneca K.K., Mitsubishi Tanabe Pharma Corporation, and Novo Nordisk Pharma Ltd., and lecture fees from Sanofi K.K.; Eli Lilly Japan K.K.; Novo Nordisk Pharma Ltd.; Sumitomo Dainippon Pharma Co., Ltd.; Ono Pharmaceutical Co., Ltd.; AstraZeneca K.K.; Mitsubishi Tanabe Pharma Corporation; and Kowa Company, Limited. All funding agencies had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. SH1, FS, SH2, SM, NS, MH, and TI declare that they have no conflicts of interest.